Sign in

Juan C. Osorio MD

@juanosoriomd.bsky.social
1.9K followers 304 following 23 posts

Assist Attending & Medical oncologist MSKCC & Rockefeller University | Antibody biology | Cancer immunology | GMO, GU | @MSK, @WeillCornellMed @BWH @UNAL | 🇨🇴🏳️‍🌈 www.mskcc.org/research-areas/labs/j…

PostsRepliesMedia
Reposted by Juan C. Osorio MD
MSK Department of Medicine @mskdeptofmed.bsky.social · 20/04/2026
Up next at #AACR26: Dr. Juan Osorio is chairing a session on advances in therapeutic antibodies, a rapidly evolving frontier in #cancer care. @mskcancercenter.bsky.social @theaacr.bsky.social @juanosoriomd.bsky.social ⏰ 2:30 p.m. PDT bit.ly/4myt3tk
032
Reposted by Juan C. Osorio MD
ACIR @acir-org.bsky.social · 20/08/2025
An agonist anti-CD40 with enhanced binding to FcγRIIB showed early promise in a small cohort of patients with metastatic melanoma. Read our digest here 👉 bit.ly/4nc91nR  @juanosoriomd.bsky.social‬  @mskcancercenter.bsky.social‬
072
Juan C. Osorio MD @juanosoriomd.bsky.social · 15/08/2025
Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work at the Ravetch lab led to this moment, made possible by an amazing team! 🧵 🪡 www.cell.com/cancer-cell/...
cell.com
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
Osorio et al. report a first-in-human study of intratumoral 2141-V11, an Fc-engineered CD40 agonistic antibody, showing it is safe and induces systemic and durable antitumor immunity in patients with ...
1135
Reposted by Juan C. Osorio MD
Society for Immunotherapy of Cancer @sitcancer.bsky.social · 07/07/2025
Anti-CD47/CD40 antibodies are emerging as new IO treatment options! Explore recent updates on these antibodies with an expert presentation from a former SITC abstract presenter @juanosoriomd.bsky.social at the 29th JACI Annual Meeting July 24-26 in Japan or virtual: ow.ly/O36B50W0cVS 🧪 #OncSky
Anti-CD47/CD40 antibodies are emerging as new IO treatment options! Explore recent updates on these antibodies with an expert presentation from a former SITC abstract presenter 
@juanosoriomd.bsky.social at the 29th JACI Annual Meeting July 24-26 in Japan or virtual: https://ow.ly/O36B50W0cVS 🧪

#OncSky
021
Juan C. Osorio MD @juanosoriomd.bsky.social · 23/05/2025
Join us at #CICON25, September 10-12 in Utrecht. This is an exciting venue to explore how novel insights in immuno-oncology can translate into life-changing outcomes! Review the program, submit an abstract and register today: bit.ly/4cjiDJ4 cancerimmunotherapyconference.org
030
Reposted by Juan C. Osorio MD
American Association for Cancer Research (AACR) @theaacr.bsky.social · 14/05/2025
Biologics and T-cell Engagers: Researchers shared updates on cutting-edge immunotherapies during this #AACR25 Clinical Trials Plenary Session. Read a recap in AACR Annual Meeting News: www.aacrmeetingnews.org/news/cutting... @juanosoriomd.bsky.social
071
Juan C. Osorio MD @juanosoriomd.bsky.social · 28/04/2025
Excited for tomorrow! 👇 #AACR25
051
Juan C. Osorio MD @juanosoriomd.bsky.social · 24/04/2025
Interested in assessing antibody-dependent cellular phagocytosis by primary macrophages? Here is a practical and optimized protocol developed by dedicated and talented members of the lab, enjoy! www.sciencedirect.com/science/arti...
sciencedirect.com
Protocol for assessing antibody-dependent cellular phagocytosis by primary murine and human macrophages
Macrophages play a crucial role in mediating antibody-dependent cellular phagocytosis (ADCP), a process that enhances the effectiveness of several can…
050
Juan C. Osorio MD @juanosoriomd.bsky.social · 14/04/2025
Interested in myeloid cell anti-tumor immunity? I’ll be presenting at the NIH/NCI Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity urldefense.com/v3/__https:/...
urldefense.com
Cassyni | Science starts with a seminar
Seamlessly organise, run and publish academic research seminars. Get started in minutes.
041
Juan C. Osorio MD @juanosoriomd.bsky.social · 31/03/2025
Thrilled to present at @theaacr.bsky.social annual meeting at the Clinical Trials Plenary Session on Biologics and T-cell Engagers! See you there to present some exciting data on our Fc-engineered CD40 agonistic antibody #AACR25
040
Reposted by Juan C. Osorio MD
Nature Cancer @natcancer.nature.com · 22/03/2025
Betty Kim & Wen Jiang and colleagues report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models. @bettykimmdphd.bsky.social @wenjiang-nano.bsky.social @mdanderson.bsky.social ⬇️ www.nature.com/articles/s43...
nature.com
An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy - Nature Cancer
Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.
11710
Reposted by Juan C. Osorio MD
Nature Reviews Immunology @natrevimmunol.nature.com · 20/03/2025
New Perspective article from Scott McConnell & @acasadevall1.bsky.social @johnshopkinssph.bsky.social highlights the importance of constant regions in influencing the specificity and functionality of #antibodies #immunology #immunosky
nature.com
New insights into antibody structure with implications for specificity, variable region restriction and isotype choice - Nature Reviews Immunology
Immunoglobulins sample vast swathes of primary sequence and conformational space to generate and select B cell clones with exquisite selectivity and affinity for specific antigens. This Perspective article examines the interplay between antibody diversification mechanisms and highlights the importance of constant regions in influencing the specificity and functionality of individual antibodies.
0194
Juan C. Osorio MD @juanosoriomd.bsky.social · 11/03/2025
Curious if people are starting to receive NOAs more recently? Whether any signs of normalcy or whether the waiting still continues? Are these categories 1-4 now in action?
000
Juan C. Osorio MD @juanosoriomd.bsky.social · 07/03/2025
Science not silence
030
Juan C. Osorio MD @juanosoriomd.bsky.social · 07/03/2025
So needed at this moment
030
Reposted by Juan C. Osorio MD
Judd Legum @juddlegum.bsky.social · 24/02/2025
1. UPDATE The NIH is still blocking most ongoing scientific funding over concerns about DEI, according to NIH sources and internal NIH correspondence. The freeze has continued even after top NIH officials acknowledged that continuing to block the funding would violate a federal court order.
popular.info
UPDATE: NIH reimposes "DEI" funding freeze despite court order
The National Institutes of Health (NIH) is still blocking most ongoing scientific funding over concerns about "diversity, equity and inclusion" (DEI), according to NIH sources and internal NIH corresp...
401360593
Juan C. Osorio MD @juanosoriomd.bsky.social · 23/02/2025
www.science.org/content/arti...
science.org
U.S. early-career researchers struggling amid chaos
Uncertain funding, government firings, and distressed universities hit vulnerable groups especially hard
031
Reposted by Juan C. Osorio MD
VJOncology @vjoncology.bsky.social · 02/01/2025
🎥 @juanosoriomd.bsky.social discusses a Phase I study on 2141-V11, an anti-CD40 antibody designed to enhance FcγRIIB binding, aiming to improve tumor response & reduce toxicity: ➡️ buff.ly/3BCEtJL ⬅️ @sitcancer.bsky.social #SITC24 #Immunotherapy
buff.ly
2141-V11: an anti-CD40 monoclonal antibody for tumor regression in patients with metastatic cancer - VJOncology
Juan Osorio, MD, Memorial Sloan Kettering Cancer Center, The Rockefeller University, New York, NY, introduces an in-human Phase I study...
061
Juan C. Osorio MD @juanosoriomd.bsky.social · 09/12/2024
Thrilled to present our for on this co-“stimulating” session organized by @sitcancer.bsky.social Join us this Thursday! Moderated by leaders in the field and presentations of exciting progress in IO for cancer. sitcancer.org/education/we...
061
Juan C. Osorio MD @juanosoriomd.bsky.social · 13/11/2024
Taking a deep breath, hoping this is a brighter sky
050